New Approaches to Facilitate Drug Discovery and Development

New Approaches to Facilitate Drug Discovery and Development

Date: 2024/12/16  13:30 - 17:00

Location: TRPMA Conference Hall (1F, Nº 465-1, Sec. 6, Chung-hsiao E. Rd., Nan-kang Dist., Taipei City 11557, TAIWAN)

Organizer: Trpma    Medicilon

Agenda：

Medicilon 

Medicilon is a leading global integrated pharmaceutical R&D CRO that provides a full range of one-stop preclinical R&D services, in compliance with global regulatory filing standards, to pharmaceutical companies and research institutions world-wide. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in Drug Discovery, Pharmaceutical Research, and Preclinical Research, to provide comprehensive preclinical R&D services for the global biomedical industry. 

Speaker Bio 

Jinna Cai, PhD 

CBO 

Dr. Cai completed her whole high-level education at China Pharmaceutical University from Bachelor to Ph.D. Conducted research with Medical University of Toyama and Institution of Natural Medicine cooperatively. Later, she worked at Chinese Academy of Sciences Shanghai Institute of Materia Medica.

Over 30 years of dedication in new drug development and research. Was awarded the first Prize for Science and Technology Progress by State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. Worked for Huiren Group as director of R&D Center for 5 years. Was awarded one of the top 10 employees by Huiren Group in 2006 and Excellent Management Individual of Provincial Technological Center during the “10th –five-year “by Jiangxi Province.

Dr. Cai joined Medicilon in July 2008 and took on the position of BD Head of Chinese market and then Vice President of BD Department.

Baohong Cao, PhD 

VP of Pharmacology 

Over twenty-five years of combined professional experience in Academic research and Pharmaceutical industry and over 10 years of people/team manage experience. Surgery Ph.D. in Beijing Medical University, post-doctoral research associate at State Serum Institute, Copenhagen, Denmark. Dr. Cao used to do research work at University of Pittsburgh & Children’s Hospital of Pittsburgh, Benaroya Research Institute (Seattle) and Novartis Institutes of Biomedical Research. His work was published by top academic magazines, such as Nature Cell Biology, Nature Biotechnology and Journal of Cell Biology. Prior to Medicilon, Dr. Cao worked for Shanghai ChemPartner Co., Ltd. as senior director, MI Bioresearch Inc. as study operations director and Wuxi Apptech Inc. as senior director in Immune oncology.

Jen-Tsung Hsieh, PhD, DABT 

VP of Toxicology Research 

Dr Hsieh is the VP of toxicology research at Medicilon. He received a PhD in Pharmacology and Toxicology from the University of Mississippi Medical Center, USA. He is also a certified DABT Toxicologist. Dr Hsieh has been in the pharmaceutical industry for more than 30 years with 12 years as a Pharm/Tox reviewer at CDE, Taiwan. Before joining Medicilon, Dr Hsieh served as a senior executive in Jiangxi Changpharma Inc., LongBio Pharma, and Oneness Biotech. Dr Hsieh’s career spans health authority, biotech companies and CRO with extensive experience in Regulatory Affairs, industrial R&D of new drugs and team management. 

Ryan Lee, PhD 

Associate Director of BD (Taiwan) 

Ryan is a versatile professional who has always been interested in how the pharmaceutical industry converts innovative ideas into therapeutic opportunities to advance public health. He graduated from the University of Nottingham, UK, with a PhD in Pharmaceutical Sciences. In addition to specialize in Regulatory Affairs and having achieved "an IND per year" company goal for three consecutive years for a liposomal company and an MAA approval of a biosimilar, currently he is completing an Elite MBA at National Taiwan University with the objective to bridge the gaps of a Development-Only-No-Research business model widely adopted by the biotech companies nowadays.